Power Law company profile

KalVista Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2011 · IPO 2016 Unicorn

Oral small-molecule protease inhibitors for rare diseases

Valuation

$1.27B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

7 investors on KalVista Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

SV Health Investors

Novo Seeds

Novo Holdings

Series B+ 4 investors entered at this stage

Venrock

Longwood Fund

RA Capital Management

University of Utah

Global footprint

Where KalVista Pharmaceuticals has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Web traffic by country

10K monthly visits
across markets

🇺🇸 United States53%

🇮🇳 India24%

🇵🇭 Philippines10%

🇩🇪 Germany7%

🇬🇧 United Kingdom7%

Top 5 markets shown

Market sentiment

What the market is saying about KalVista Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about KalVista Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See KalVista Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles